(Date:11/19/2009)... WALTHAM, Mass., Nov. 19 Arlington...nd that the leading driver of antibiotic selection...um activity against gram-positive and gram-negativ...can cause nosocomial pneumonia, surveyed European ...nts that provide appropriate coverage against comm...
(Date:11/19/2009)...RNewswire/ - Aegera Therapeutics Inc. announced to...d Phase 2B study of AEG35156, a targeted antisense... oncology indications. ,, The study, entitled "...nked Inhibitor of Apoptosis (XIAP) Antisense AEG35... and Idarubicin in AML Following Failure of a Sing...
(Date:11/19/2009)...,s Top Gene Synthesis Companies Form International...st Practices in Risk Reduction ,Five Member Comp...esis Capacity , (PRWEB) N...ing gene synthesis companies today announced agree...col to promote biosecurity in the gene synthesis i...
(Date:11/19/2009)...ria, November 19 AFFiRiS AG will f...t candidate at an unexpectedly early,stage of deve...enter into,Phase II clinical trial early in 2010. ...he completion of two Phase I trials with the candi...cision on the first interim,analysis of the second...
Breaking Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3...th Systems, Inc. (Nasdaq: DCTH ), a medical tec...us Hepatic Perfusion ("PHP") System for the treatm...the first fifty percent (46 of 92) of patients hav...eating metastatic cutaneous and ocular melanoma to...rs in this trial continue to evaluate and enroll p...
...1 , - SCRIP Awards Recognises the Best and Brig...stries Worldwide, - Glenmark is the Only Indian...ecognition, , The best and brightest of the ...ted at a glittering ceremony in London at the 2008... Peter Sissons on December 10th. At this award,cer...
...iate Action to Protect and Maximize Shareholder Va... Fund, L.P., the owner, together with its affiliat...mon stock of Avigen, Inc. (Nasdaq: AVGN ) announ...,s Board of Directors expressing its displeasure w...ruction of shareholder value. , , The text ...
Other Biology Technology:Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5Macrophage Differentiation Kit from 3H Biomedical AB
Goat Anti-HAS1 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Frozen Tissue Section Panel - Monkey (Rhesus) Normal Tissue, Multi-tissue I from BioChain
Frozen Tissue Section Panel - Monkey (Cynomolgus) Normal Tissue, Multi-tissue I from BioChain
Biology Products: